Cargando…
Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review
The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851664/ https://www.ncbi.nlm.nih.gov/pubmed/31407842 http://dx.doi.org/10.1002/ajmg.a.61324 |
_version_ | 1783469662268293120 |
---|---|
author | de Boer, Janna Boot, Erik van Gils, Lissa van Amelsvoort, Therese Zinkstok, Janneke |
author_facet | de Boer, Janna Boot, Erik van Gils, Lissa van Amelsvoort, Therese Zinkstok, Janneke |
author_sort | de Boer, Janna |
collection | PubMed |
description | The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic medication, we carried out a literature review. A systematic search strategy was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Publications describing adverse effects of antipsychotic medication in patients with 22q11.2DS were included in the review and assessed for their methodological quality. A total of 11 publications reporting on eight trials, cross‐sectional or cohort studies, and 30 case reports were included. The most commonly reported adverse effects can be classified into the following categories: movement disorders, weight gain, seizures, cardiac side effects, and cytopenias. Many of these symptoms are manifestations of 22q11.2DS, also in the absence of antipsychotic medication. Based on the reviewed literature, a causal relation between antipsychotic medication and the reported adverse effects could not be established in the majority of cases. Randomized clinical trials are needed to make firm conclusions regarding risk of adverse effects of antipsychotics in patients with 22q11.2DS. |
format | Online Article Text |
id | pubmed-6851664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-68516642019-11-18 Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review de Boer, Janna Boot, Erik van Gils, Lissa van Amelsvoort, Therese Zinkstok, Janneke Am J Med Genet A Research Review The 22q11.2 deletion syndrome (22q11.2DS) is a multisystem condition and the most prevalent microdeletion syndrome in humans. Approximately 25% of individuals with 22q11.2DS receive antipsychotic treatment. To assess whether patients with 22q11.2DS are vulnerable to adverse effects of antipsychotic medication, we carried out a literature review. A systematic search strategy was performed using PubMed (Medline), Embase, PsychInfo, and Cochrane Database of Systematic Reviews. Publications describing adverse effects of antipsychotic medication in patients with 22q11.2DS were included in the review and assessed for their methodological quality. A total of 11 publications reporting on eight trials, cross‐sectional or cohort studies, and 30 case reports were included. The most commonly reported adverse effects can be classified into the following categories: movement disorders, weight gain, seizures, cardiac side effects, and cytopenias. Many of these symptoms are manifestations of 22q11.2DS, also in the absence of antipsychotic medication. Based on the reviewed literature, a causal relation between antipsychotic medication and the reported adverse effects could not be established in the majority of cases. Randomized clinical trials are needed to make firm conclusions regarding risk of adverse effects of antipsychotics in patients with 22q11.2DS. John Wiley & Sons, Inc. 2019-08-13 2019-11 /pmc/articles/PMC6851664/ /pubmed/31407842 http://dx.doi.org/10.1002/ajmg.a.61324 Text en © 2019 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Review de Boer, Janna Boot, Erik van Gils, Lissa van Amelsvoort, Therese Zinkstok, Janneke Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review |
title | Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review |
title_full | Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review |
title_fullStr | Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review |
title_full_unstemmed | Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review |
title_short | Adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: A systematic review |
title_sort | adverse effects of antipsychotic medication in patients with 22q11.2 deletion syndrome: a systematic review |
topic | Research Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851664/ https://www.ncbi.nlm.nih.gov/pubmed/31407842 http://dx.doi.org/10.1002/ajmg.a.61324 |
work_keys_str_mv | AT deboerjanna adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview AT booterik adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview AT vangilslissa adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview AT vanamelsvoorttherese adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview AT zinkstokjanneke adverseeffectsofantipsychoticmedicationinpatientswith22q112deletionsyndromeasystematicreview |